Pharmacologic Interventions to Lower hs-CRP

n this episode, Drs. Brittany Weber and Michael Garshick discuss "Pharmacologic Interventions to Lower hs-CRP." This podcast is part of the Inflammation in Cardiovascular Health: Raising Awareness of the Increasing Role of hs-CRP grant initiative.

Educational support for this initiative is provided by Novo Nordisk.

Click here to learn more.

Related References:

1. Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847.

1. Ridker PM. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Circulation. 2020;141(10):787-789.

1. Ridker PM. From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138-e140.

1. Ridker PM, Bhatt DL, Pradhan AD, et al; PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293-1301.

1. Ridker PM, Moorthy MV, Cook NR, et al. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024;391(22):2087-2097.

1. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505.

Subscribe to CardiaCast